Adlai Nortye logo
Adlai Nortye
ANL | NASDAQ
Chart Builder DCF Calculator
$10.03
-$0.58 (-5.47%)
At close: Nov 16, 2026, 4:00 PM ET
$10.03
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Adlai Nortye Company Profile

Company profile explained

Company Profile

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

Key Executives

Name Position
Yang Lu Co- Founder, Chief Executive Officer & Chairman
Xiaofeng Ye Chief Financial Officer
Chen Yang Head of HR & Administration & Government Affairs
Christopher Liu Head of Investor Relations & Public Relations
Donghui Yang Chairman of the Greater China Region
Nanhai He Head of Discovery
Ngai Chiu Tse President & Head of Research & Development
Zhiyong Yu Vice President of Operations

Latest SEC Filings

Date Type Title
Oct 28, 2026 6-K Filing
Oct 15, 2026 6-K Filing
Oct 01, 2026 4 Filing
Sep 30, 2026 6-K Filing
Sep 30, 2026 6-K Filing
Sep 24, 2026 4 Filing
Sep 15, 2026 EFFECT Filing
Sep 11, 2026 S-8 POS Filing
Sep 11, 2026 S-8 POS Filing
Sep 11, 2026 POS AM Filing
View All SEC Filings ➞
Adlai Nortye
Adlai Nortye logo
Country Singapore
IPO Date Sep 29, 2023
Industry Biotechnology
Sector Healthcare
Employees 109
CEO Yang Lu

Contact Details

77 Robinson Road, #20-01, Robinson 77 Singapore 068896 Singapore

Stock Details

Ticker Symbol ANL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001944552
CUSIP Number 00704R109
ISIN Number US00704R1095
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.